939307
Protein delivery system
Human BDNF, PODS®
Synonyme(s) :
PODS®
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
A propos de cet article
NACRES:
NA.21
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderService technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Protein delivery system, Human BDNF, PODS®
biological source
(Spodoptera frugiperda (Sf9) cell culture)
form
(monodisperse crystals)
packaging
1 ea of 25 μg
technique(s)
: suitable using 3D bioprinting | cell culture
impurities
<0.06 EU/mL Endotoxin
color
colorless
storage temp.
2-8°C
Quality Level
Vous recherchez des produits similaires ? Visite Guide de comparaison des produits
Application
PODS are composed of a bioactive cargo protein within a polyhedrin crystal lattice, with polyhedrin as the main protein. The 25 µg SKU size indicates the amount of bioactive cargo, typically 0.5% to 5% of the total protein. For instance, a 25 µg SKU at a 2% cargo loading contains 1.25 mg of total protein. PODS enable sustained release of cargo proteins when proteases degrade the polyhedrin scaffold. Growth factors are not bioavailable until released, and their concentration in media depends on the amount added and the release rate. In 10% serum, peak levels are usually reached within 24-48 hours, with about 20% of the cargo becoming soluble.
PODS often require lower concentrations than conventional growth factors, as they maintain effective levels. Pre-incubating with serum or proteases enhances availability, while conventional factors can be added for immediate effects. Optimal amounts should be determined empirically.
PODS often require lower concentrations than conventional growth factors, as they maintain effective levels. Pre-incubating with serum or proteases enhances availability, while conventional factors can be added for immediate effects. Optimal amounts should be determined empirically.
Features and Benefits
- Protein delivery system, PODS Human BDNF comes with molecular weight of 37.6 kDa, length 164 aa, with endotoxin level of <0.06 EU/ml as measured by gel clot LAL assay. PODS co-crystals may be reconstituted at 200 million co-crystals/ml in sterile PBS. 20% glucose has a buoyant density closer to PODS co-crystals and can be useful for aliquoting.
- This product is produced with no animal derived raw products. All processing and handling employs animal free equipment and animal free protocols. PODS co-crystals are highly stable when stored in aqueous solution (pH range 6 - 8).
- PODS provides durability, stability AND sustained release, addressing the limitations of conventional and enabling researchers to effortlessly control and manipulate cells in 2D and 3D culture as well as in-vivo.
General description
Protein delivery system, PODS Human BDNF contains the polyhedrin protein co-crystalized with human Brain-derived neurotrophic factor (BDNF) which a protein that plays a crucial role in the growth, development, and maintenance of neurons in the brain. BDNF binds two receptors, the low-affinity nerve growth factor receptor (LNGFR) and the tropomyosin receptor kinase B (TrkB), to support neuron growth and survival. BDNF expression in the hippocampus is essential for long-term memory storage and learning. Some protein domains of BDNF are identical with those of NGF and another neurotrophic factor, designated NT-3 (Neurotrophin-3). Human, mouse, rat, and pig BDNF are cross-reactive.
Legal Information
PODS is a registered trademark of Cell Guidance Systems Ltd
Classe de stockage
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Nano-particle delivery of brain derived neurotrophic factor after focal cerebral ischemia reduces tissue injury and enhances behavioral recovery
Harris M N, et al.
Pharmacology, Biochemistry, and Behavior, 150-151, 48-56 (2016)
From Molecular to Nanotechnology Strategies for Delivery of Neurotrophins: Emphasis on Brain-Derived Neurotrophic Factor (BDNF)
Geral C, et al.
Pharmaceutics, 5(1), 127-167 (2013)
Brain-Derived Neurotrophic Factor and Its Potential Therapeutic Role in Stroke Comorbidities
Liu W, et al.
Neural Plast. (2020)
Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..
Contacter notre Service technique